Suprecur

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Suprecur

What is Suprecur?

Suprecur is a medicinal product containing the active substance buserelin. It belongs to a group of medicines known as gonadotrophin-releasing hormone (GnRH) analogues. These are synthetic variations of a naturally occurring hormone that regulates the production of reproductive hormones in the body.

Mechanism of Action

Buserelin works by acting on the pituitary gland. When administered, it initially stimulates the release of hormones that prompt the ovaries or testes to produce estrogen or testosterone. However, with continuous use, it leads to a downregulation of the pituitary gland's receptors. This process results in a significant reduction in the production of these sex hormones, bringing them down to very low levels.

Therapeutic Use

By modulating the hormonal environment, Suprecur is utilized in the management of conditions that are sensitive to sex hormones. In reproductive medicine, it is frequently used to control the menstrual cycle during assisted reproduction treatments, such as in vitro fertilisation (IVF). By suppressing the natural surge of hormones, it allows clinicians to better manage the timing of egg maturation.

Additionally, it is used in the treatment of endometriosis, a condition where tissue similar to the lining of the womb grows in other areas of the body. By lowering estrogen levels, Suprecur helps to thin this tissue and alleviate associated symptoms. It may also be used in the management of uterine fibroids by reducing their size through hormonal suppression.

Regulatory References

  1. MedlinePlus Buserelin Injection

What side effects are possible with Suprecur?

Possible Side Effects and Safety Information

The official safety profile of Suprecur (Buserelin) is primarily characterized by adverse reactions resulting from its intended effect of inducing a low sex hormone state (hypoestrogenism/hypoandrogenism).


Frequency-Classified Adverse Reactions

Adverse effects are formally classified in regulatory documents:

  • Common: The most frequently documented reactions include hot flushes and sweats, headache, fatigue, mood disturbances (such as depression and anxiety), and changes in sexual function (e.g., decreased libido and impotence/vaginal dryness). Local injection site reactions are also common.
  • Rare: Less frequently documented reactions include severe generalized allergic reactions (anaphylaxis), and reports of pituitary apoplexy, typically occurring in patients with pre-existing pituitary adenomas.

Serious and Population-Specific Safety Considerations

Official labeling highlights specific risks relevant to treatment duration and patient groups:

  • Serious Adverse Reactions: The Tumour Flare Phenomenon, a transient worsening of symptoms (e.g., bone pain, spinal cord compression) may occur during the initial weeks of therapy in men with prostate cancer. An increased risk of serious cardiovascular events (myocardial infarction, stroke) is also documented in men receiving GnRH agonists.
  • Long-Term Exposure: Use is associated with a risk of decreased bone mineral density and fracture, particularly during long-term use.
  • Specific Populations: Caution is officially advised for patients with a history of diabetes or depression. Monitoring of blood glucose is noted as necessary for diabetic patients. Vaginal bleeding or spotting may frequently occur during the early stages of treatment in women.
  • Restrictions: Buserelin is officially contraindicated during pregnancy and lactation.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information details the officially documented manifestations of Buserelin (Suprecur/Suprefact) overdose and the immediate actions mandated by regulatory authorities. This content is strictly based on government-approved prescribing information.

Documented Manifestations of Overdose

Official labeling indicates that exceeding the prescribed dosage may result in specific clinical signs. These manifestations are typically systemic and may include feeling weak, feeling nervous, headache, and dizziness. Gastrointestinal symptoms such as stomach pain and nausea are also documented. Other possible documented signs include hot flushes, breast pain, and swelling of the legs, along with localized reactions at the injection site such as pain, bleeding, or hardening of the skin.

Required Emergency Action

In all cases of suspected overdose, regulatory guidance requires immediate attention. You must tell a doctor straight away and go to a hospital casualty department straight away. This mandated action applies regardless of the severity of the symptoms presented. The official product documentation indicates that the management of overdose is symptomatic in nature, as no specific antidote is known. Regulatory assessments affirm that the acute toxicity of Buserelin is generally considered low, making severe signs unlikely even if the recommended dose is exceeded.

Therapeutic Uses of Suprecur

What Suprecur Treats: Main Uses and Benefits

Suprecur (Buserelin) is commonly used and is relevant in situations involving certain distressing symptoms. It provides supportive therapeutic benefit by addressing conditions where functional stability may be affected. Its uses span major therapeutic domains.

The medication is commonly used across conditions presenting with disruptive episodes, including: advanced prostate carcinoma, endometriosis, uterine fibroids, and Central Precocious Puberty (CPP), and as a supportive measure in Assisted Reproductive Technology (ART). The core benefit is to apply supportive symptomatic management in these conditions.

“The therapy is applied in clinical settings where the primary goal is to provide supportive symptomatic management.”

This approach assists patients with maintaining functional stability and helps them cope more steadily with symptom fluctuations.

Quick Fact: Relief for Physical Discomfort The treatment contributes to improved day-to-day comfort during symptomatic periods of chronic pelvic pain and heavy menstrual bleeding, assisting with managing these symptoms.

Regulatory References

  1. Health Canada-affiliated Drug Manual on Buserelin

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adult Men for the treatment of hormone-dependent advanced prostate carcinoma.
  • Adult Women for the treatment of endometriosis, uterine fibroids, and for down-regulation in Assisted Reproductive Technology (ART).
  • Pediatric Patients for the treatment of Central Precocious Puberty (CPP).

Populations for whom use is contraindicated:

  • Patients with known hypersensitivity to Buserelin, GnRH, or any excipients.
  • Pregnant or breastfeeding women.
  • Women with undiagnosed abnormal vaginal bleeding.
  • Men who have undergone orchiectomy or whose prostate cancer is not hormone-dependent.

Condition-Specific Eligibility Rules

Use requires careful monitoring or is restricted in the following patient groups, as noted in regulatory warnings:

  • Individuals with a history of depression due to the risk of recurrence or worsening of the condition.
  • Patients with Diabetes Mellitus or cardiovascular disease (in men) due to reported risks and the need for metabolic/cardiac monitoring.
  • Individuals with risk factors for osteoporosis or with severe hepatic or renal impairment (due to excipient accumulation risk).

Pregnancy and Lactation Eligibility Status

  • Pregnancy: Contraindicated.
  • Lactation: Contraindicated.

Connection to the overall eligibility profile: Official regulatory documents define patient eligibility by imposing absolute contraindications (e.g., pregnancy, hypersensitivity) and specifying allowed use for labeled indications across adult and pediatric populations. The documents further establish conditional restrictions, requiring special caution and ongoing monitoring for individuals with certain pre-existing comorbidities like diabetes or depression.

What should I know about interactions with other medicines?

Pharmacodynamic Antagonism

A documented pharmacodynamic interaction exists with other sex hormones. Co-administration of medicinal products containing estrogens or androgens is officially noted to potentially exert an antagonistic effect on buserelin. As the primary action of buserelin is to suppress endogenous sex hormone levels, the concurrent use of these hormonal products may directly and significantly counteract the intended suppressive outcome.

Exposure-Modifying and Timing Restriction

A separate, administration-dependent interaction is noted for the intranasal solution dosage form. The systemic absorption of buserelin may be decreased when co-administered with other nasal preparations, particularly those that may affect the nasal mucosa, such as topical decongestants. This is classified as an exposure-modifying interaction, as the reduced absorption leads to a lower concentration of the medicine in the bloodstream. To mitigate this risk, government labeling specifies a mandatory timing rule: any other nasal preparation must be administered at least 30 minutes after the Buserelin nasal dose to ensure the medicine has been adequately absorbed. No clinically significant interactions involving common metabolic pathways, such as CYP enzymes, or interactions with food, alcohol, or herbal products are officially documented.

Mechanism of Action

How Suprecur Works: The Mechanism of Action

Buserelin's action is defined by a two-stage functional alteration of the central endocrine system, initiated by targeting receptors in the pituitary gland.

The drug acts as a superagonist to the GnRH receptor on pituitary cells. This potent binding initially forces a strong, but temporary, activation. However, sustained exposure to the drug causes these receptors to become profoundly down-regulated and functionally desensitized. This property is the initial step that leads to a profound reduction in the pituitary's responsiveness to further hormonal signals.

This chronic receptor non-responsiveness leads to the sustained functional suppression of the Hypothalamic-Pituitary-Gonadal (HPG) Axis. The pituitary ceases the release of its effector hormones, LH and FSH. This functional cessation of secretion removes the necessary pituitary signals ( LH and FSH) required to stimulate the testes and ovaries, resulting in a profound arrest of gonadal steroidogenesis.

The ultimate physiological effect is a sustained reduction of circulating sex hormones ( testosterone and estradiol) to levels characteristic of post-menopausal or castrate status. The initial mechanism includes a temporary hormone flare due to initial agonism; the chronic action subsequently establishes a reversible hypogonadal state that represents the key physiological consequence of the drug's targeted cascade.

Dosage and Administration Information

Suprecur (Buserelin) is provided as a solution for subcutaneous injection and an intranasal solution (nasal spray), with the appropriate form and regimen strictly defined by the treatment course. Guidelines emphasize that all individual doses must be administered at approximately equal intervals throughout the day to ensure the desired continuous effect.

The administration protocol varies significantly based on the clinical context:

Clinical Context Initial Route & Regimen Maintenance Protocol
Prostatic Carcinoma Subcutaneous injection of 0.5 mg every 8 hours (3 times daily). Intranasal spray of 100 micrograms per nostril, 6 times daily.
ART Downregulation Subcutaneous injection of 200 – 500 micrograms once daily. Dosage is maintained until pituitary down-regulation is confirmed.

The initiation of the Prostatic Carcinoma regimen is advised to be carried out in hospital for proper supervision of the 7-day loading phase. The subcutaneous injection solution must be visually checked and should be clear and colourless before use; any discoloration requires disposal.

For Assisted Reproductive Technology (ART), the subcutaneous injection must be commenced on a specific day—either the early follicular phase (Day 1 or 2) or the mid-luteal phase of the menstrual cycle. The typical duration for this downregulation phase is 1 to 3 weeks. If a dose is missed, the patient should resume the schedule as soon as possible, but must never take a double dose to make up for the missed one.

Recent Clinical Evidence

Research evidence / Overview of studies for Suprecur (Buserelin)


Evidence for Oncological and Pediatric Uses

Research on Advanced Prostate Carcinoma primarily relies on Randomized Controlled Trials (RCTs) and long-term observational studies. These studies examine changes in the biomarker Prostate-Specific Antigen (PSA) levels and documentation of overall survival times in adult and older adult men. For Central Precocious Puberty (CPP), studies are multi-year and longitudinal, focusing on children. Researchers track hormonal suppression and the observed patterns in pubertal sign development, including the measurement of final adult height. In both areas, Buserelin use was associated with the intended suppression of sex steroid hormones, a pattern consistent with the GnRH agonist class.


Evidence for Gynecological and ART Uses

For endometriosis, studies are typically short-term RCTs that track patient-reported symptom scores for pain and discomfort, alongside measurements of estrogen levels consistent with a suppressed state in women of reproductive age. Research for Assisted Reproductive Technology (ART) involves comparative RCTs that monitor acute outcomes within a single cycle, focusing on gonadotropin suppression and observed clinical pregnancy rates. A key limitation across gynecological indications is that follow-up studies sometimes describe symptom recurrence patterns after treatment is completed.


Research Gaps and Limitations

The evidence base includes studies specifically evaluating distinct populations, such as older men (prostate carcinoma) and the pediatric population (CPP). However, long-term data regarding the persistence of observed symptom patterns beyond the intermediate post-treatment period for gynecological uses are often not well characterized by extensive longitudinal research. This indicates areas where further data collection or analysis is documented as ongoing or needed. Furthermore, there is a noted variability in findings when comparing Buserelin protocols with contemporary regimens in ART.

Key Studies & References

  1. Systematic Review: GnRH agonists for women with symptomatic endometriosis (A systematic review and meta-analysis of randomized controlled trials)
  2. Clinical Trials Database (WHO ICTRP/NIH): Buserelin trials in Central Precocious Puberty
  3. NIH MedlinePlus: Buserelin Injection

Frequently Asked Questions (FAQ)

Common questions about Suprecur (FAQ)


Q: Is Suprecur the same as other GnRH agonists?

Suprecur, which contains the active ingredient Buserelin, belongs to a class of medications called GnRH agonists. Official documents confirm that all drugs in this class share the same fundamental mechanism: they first stimulate, then chronically suppress, the central hormone system. While the underlying action is similar, each drug in the class has unique properties, preparations, and specific indications.


Q: Are there any long-term side effects to worry about after stopping Suprecur?

The hormonal effects of Suprecur are intended to be reversible once treatment is stopped. The recovery of normal reproductive hormone function typically occurs within approximately two months after discontinuation. Regulatory warnings indicate that changes in bone mass are generally expected to be reversible, though the timeline for recovery may take 18-24 months after stopping the medication.


Q: Does Suprecur interact with birth control pills?

Yes, official product information advises that Suprecur should not be used concurrently with hormonal contraceptives, such as the Pill or the mini Pill. Using these together may counteract the intended hormone-suppressing effect of Suprecur. Regulatory documents recommend that non-hormonal contraception be considered while using this medication.


Q: Are allergic reactions to Suprecur rare or common?

Official safety data classifies severe, widespread allergic reactions, such as anaphylaxis, as Very Rare. However, localized reactions at the site of injection, such as redness or pain, are documented as a Common side effect. Concerns regarding potential allergic reactions should be discussed with a healthcare professional.


Q: Does Suprecur require any special storage conditions?

Yes, proper storage is necessary to maintain the medication’s integrity. The injection solution should not be stored above 25 °C (77 °F) and must not be frozen. To ensure stability, all forms of the medication must be kept in the original outer carton to protect them from light.


Q: What age range is Suprecur typically prescribed for in cases of central precocious puberty?

Suprecur is indicated for Central Precocious Puberty (CPP), which is defined as the onset of puberty that occurs too early. This condition is typically diagnosed when pubertal signs begin before the age of 8 years in girls and before the age of 9 years in boys.


Q: Can Suprecur cause changes in vision?

Yes, official labeling lists some uncommon side effects related to vision. These can include impaired vision (such as blurred vision), dry eyes, or a feeling of pressure behind the eyes. Any persistent visual changes should be discussed with a healthcare professional.


Q: How long after stopping Suprecur will my normal menstrual cycle return?

The return of normal menstrual cycles and ovulation is a sign that the body’s hormone system has recovered from the suppressive effect of the medication. For most women, menstruation typically returns within 4 to 10 weeks after the last dose, although this timeframe can vary widely between individuals.


Q: Will Suprecur affect my ability to drive or operate machinery?

Yes, official product information advises caution because certain side effects may affect concentration. Effects like dizziness, drowsiness, and blurred vision, which are reported with Buserelin therapy, may impair the ability to concentrate and react, which is relevant when operating a vehicle or machinery.


Q: Can Suprecur be used in patients with a history of heart problems?

Caution and regular monitoring are advised for patients with existing heart or blood vessel conditions. Official warnings note that the risk of heart rhythm problems, or arrhythmia, may be slightly increased with this class of medication. Official labeling states that use in these patients requires medical monitoring and discussion.


Q: What should I do if the Suprecur nasal spray causes nasal irritation?

Nasal irritation, dryness, or nosebleeds are known local side effects of the nasal solution. If the irritation becomes troublesome or persistent, the issue should be discussed with a healthcare provider.


Q: Does Suprecur cause weight gain, and is it reversible?

Official documents report that both weight gain and weight loss have been documented as side effects of Suprecur therapy, due to the changes in the endocrine system. There is no specific statement in regulatory documents guaranteeing the reversibility of weight changes upon stopping the medication.


Q: How quickly does Suprecur start to work after the first dose?

The drug’s action begins immediately after the first dose by initiating a strong but temporary stimulation of the pituitary gland. The full therapeutic effect—the sustained and profound suppression of sex hormones—is typically established after several weeks of continuous administration as the pituitary receptors become desensitized.


Q: Are headaches a common side effect of Suprecur nasal spray?

Yes, headache is classified as a Common side effect associated with Buserelin therapy, regardless of whether it is administered by injection or as a nasal spray. Headaches are a common result of the hormonal changes induced by the medication.


Q: Does Suprecur affect bone density, and what can be done about it?

Yes, long-term use is associated with a decrease in bone mineral density and an increased risk of fracture. This risk is why the treatment duration for benign conditions is usually limited to six months. Medical guidance often includes discussing preventative measures to mitigate bone loss or the recommendation of monitoring.


Q: Is it necessary to use 'add-back' therapy with Suprecur?

'Add-back' therapy involves giving small doses of hormones to help reduce the side effects of the hypoestrogenic (low hormone) state induced by Suprecur, particularly to mitigate the risk of bone loss. While the official documents do not mandate this, the documented risk of decreased bone mineral density often justifies the discussion of preventative measures like this with a healthcare provider.


Q: What kind of monitoring (blood tests) is needed while on Suprecur?

Regular patient monitoring is essential during treatment. This can include checking blood pressure and carefully monitoring blood glucose levels in patients who have diabetes. Depending on the condition being treated, medical guidance may also involve tracking hormone or cancer biomarker levels.


Q: Is it okay to use nasal decongestants while using Suprecur nasal spray?

The use of other nasal preparations, such as decongestants, is allowed but requires careful timing. Regulatory guidelines require that the other nasal product must be administered at least 30 minutes after the Suprecur dose to ensure the medication is properly absorbed into the bloodstream.


Q: Why does Suprecur treatment usually last for only six months for benign conditions?

The recommended maximum duration for treating benign conditions like endometriosis and uterine fibroids is typically six months. This time limit is imposed primarily because the risk of decreasing bone mineral density and potential fracture increases significantly with longer-term use of the medication.


Q: Does Suprecur affect sleep patterns or cause insomnia?

Yes, official safety information reports that sleep disturbances, including insomnia (difficulty sleeping), are known side effects. Additionally, common effects like tiredness or drowsiness may also affect energy and rest cycles.

How should Suprecur be stored and disposed of?

How to Store and Dispose of Suprecur?

The storage of Suprecur (Buserelin) must strictly follow official regulatory requirements to maintain product integrity.

Condition Requirement
Temperature Do not store the injection solution above 25 °C (or 77 °F) and do not freeze.
Light Protection Keep the injection vials in the outer carton to shield the medicine from light.
Post-Opening Stability The injection solution must be used within 15 days after the vial is first opened. The nasal solution is stable for up to 5 weeks after opening.

All Suprecur formulations must be kept out of the sight and reach of children. Any unused or expired medicine, along with waste materials, must be disposed of in accordance with local regulations. Used syringes and needles from the injection form must be collected and discarded safely as sharps waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Suprecur found in:

A-Z Index: